García-Martínez, PabloSitjas, DolorsLlistosella, EnricEspinet Solà, BlancaRodríoguez Rivera, MaríaGallardo Hernández, FernandoPujol Vallverdú, Ramon Maria2017-11-072017-11-072017García-Martínez P, Sitjas D, Llistosella E, Espinet B, Rodríguez-Rivera M, Hernandez-Muñoz M. Imatinib treatment of lymphomatoid papulosis associated with myeloproliferative hypereosinophilic syndrome presenting the FIP1L1-PDGFRA fusion gene. Acta Derm Venereol. 2017 Jul 6;97(7):855-857. DOI: 10.2340/00015555-26690001-5555http://hdl.handle.net/10230/33163Peripheral blood eosinophilia has been reported to occur in a wide range of haematological malignancies including primary cutaneous lymphomas. The concurrence of lymphomatoid papulosis (LyP) with peripheral blood eosinophilia seems to be an uncommon phenomenon. Atypical lymphocytes in LyP display the phenotype of activated T-helper cells, consistently express CD30 antigen, have a Th2 cytokine profile, and secrete eosinophilstimulating cytokines. Cases of LyP have been reported in association with myeloproliferative hypereosinophilic syndrome (M-HES) presenting the Fip1-like 1/plateletderived growth factor receptor-α (FIP1L1-PDGFRA) fusion gene. In such cases, imatinib treatment may lead to a complete and persistent resolution of LyP lesions.application/pdfengThis is an open access article under the CC BY-NC license. www.medicaljournals.se/acta Journal Compilation © 2017 Acta Dermato-Venereologica.Limfomes -- Tractamentinfo:eu-repo/semantics/articlehttp://dx.doi.org/10.2340/00015555-2669info:eu-repo/semantics/openAccess